The slip
PARKINSON RECEIPTno. 9039
24 Oct 2026, 21:33 UTCdopamine neurons, braak
predictionTRIP12 in dopamine neurons tracks Braak Lewy-body stage
registeredc79fdd0576f8e4d2
discovery+0.46 p=0.209 n=9
replication+0.10 p=0.807 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho +0.46, p 0.209)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECTeadabe3ae565c76bb8d97ead…
follows dadb68dba7d2…
Covered by the on-chain checkpoint of receipt 10865 (2026-10-26 13:05 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next
The swarm's case
receipt 9039: TRIP12 in dopamine neurons, braak
- power
- full sample +0.28 (p 0.261, n 18), 95% CI -0.22 to +0.66. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.28 (p 0.261, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.28 (p 0.269, n 18). could be the mix.
- skeptic
- leave-one-out range +0.19 to +0.43, sign flips 0; without severely affected donors +0.28 (p 0.261, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.73 (p 6.6e-4, n 18) vs +0.28 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TRIP12 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up TRIP12 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.52 p 0.062 (needs p < 2.3e-4)